Gut Gas Imbalances Drive Childhood Constipation, Study Finds
- Authors
- Yuewen Zhou, Enfu Tao
- Journal
- Frontiers in Nutrition
- Year
- 2026
- DOI
- 10.3389/fnut.2025.1694831
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Pediatric Functional Constipation
- Body System
- Digestive System
TL;DR
Some kids with constipation have an imbalance of gases in their gut caused by unhealthy bacteria, and too much methane gas seems to slow down their digestion—but the good news is that scientists are developing new treatments like special antibiotics and probiotics that target these gases and could help when regular laxatives don't work.
Key Finding
Elevated methane gas produced by gut bacteria correlates with delayed bowel transit and worse constipation symptoms in children, while hydrogen gas appears to enhance bowel movement.
Summary
This review examined how intestinal gases produced by gut bacteria may contribute to constipation in children. Researchers found that an imbalance in gases—particularly too much methane (which slows bowel movement) and too little hydrogen (which speeds it up)—may be a key problem in children with functional constipation (constipation without a physical blockage). The review suggests that new treatments targeting these gas imbalances, such as specific antibiotics, probiotics, and dietary changes, may help, but more research in children is needed.
Practical Takeaway
This is a review article that synthesizes existing research rather than a new study, and it does not include human trials or clinical results. While it suggests that hydrogen gas may play a beneficial role in bowel motility, the evidence discussed is preliminary and mostly from animal or mechanistic studies. Anyone considering hydrogen water or gas-targeted therapies for pediatric constipation should consult a pediatric gastroenterologist, as the review emphasizes that pediatric-specific safety data and long-term outcomes remain unexplored.
Abstract
Pediatric functional constipation (PFC) is a prevalent gastrointestinal disorder affecting approximately 18.2% of children worldwide, characterized by infrequent or painful bowel movements without organic cause, and significantly impairing quality of life, yet its management remains suboptimal. A central problem in its management is the high failure rate of conventional therapies; notably, treatments such as laxatives fail to achieve sustained relief in about 40% of pediatric patients, highlighting the critical need to explore novel pathophysiological mechanisms and therapeutic targets. Emerging evidence now highlights gut microbiota dysbiosis and the resulting imbalances in intestinal gases-particularly hydrogen (H₂), methane (CH₄), carbon dioxide (CO₂), and hydrogen sulfide (H₂S)-as key drivers of its pathophysiology. This review synthesizes current knowledge on how microbial gas metabolism influences gut motility in PFC: elevated CH₄, produced by methanogenic archaea such as Methanobrevibacter smithii, strongly correlates with delayed colonic transit and symptom severity, while H₂ enhances motility, and CO₂ and H₂S exert dose-dependent effects on peristalsis and mucosal signaling. Recent diagnostic advances, including H₂/CH₄ breath testing, electronic nose (E-nose) volatile organic compound profiling, and wireless motility capsules, enable non-invasive assessment of gas dynamics and transit, supporting precision phenotyping. Therapeutic strategies targeting gas-microbiota interactions-such as methane-lowering antibiotics (e.g., rifaximin), probiotics (e.g., Lactobacillus plantarum), low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diets, and neuromodulation-show promise, but pediatric-specific thresholds, safety, and long-term outcomes remain underexplored. The principal novelty of this review lies in its integrative framework, combining gastroenterology, microbiology, and engineering perspectives to advance gas-targeted precision medicine in PFC. Finally, we identify critical research gaps -such as the lack of pediatric-specific diagnostic thresholds and long-term therapeutic validation-and emphasize the urgent need for longitudinal studies and multidisciplinary trials to translate these insights into meaningful clinical outcomes.